Myriad Genetics, Inc. (MYGN - Free Report) was a big mover last session, as the company saw its shares rise around 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 35.7% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate, however, moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this biomedical stock going forward to see if this recent move higher can last.
Myriad Genetics currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the same industry is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , sporting a Zacks Rank #1 (Strong Buy).
Is MYGN going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Myriad Genetics, Inc. (MYGN - Free Report) was a big mover last session, as the company saw its shares rise around 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 35.7% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate, however, moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this biomedical stock going forward to see if this recent move higher can last.
Myriad Genetics currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the same industry is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , sporting a Zacks Rank #1 (Strong Buy).
Is MYGN going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MYGN - FREE
Get the latest research report on ANIP - FREE